The US will impose a 100 per cent tariff on branded or patented pharmaceutical products from October 1, 2025, unless a company is building its pharmaceutical manufacturing plant in the US, according to its President, Donald Trump.

Trump announced this on Thursday in the US. “Is building will be defined as breaking ground or under construction. There will, therefore, be no tariff on these pharmaceutical products if construction has started,’‘ Trump said in a post on X (Twitter).

While the full details are yet to be spelt out, the tariff will not be applicable to those Indian companies that already have manufacturing plants in the US, going by the definition of ‘is building’ given by Trump.

The US is the largest destination for Indian pharmaceutical exports, accounting for over one-third

See Full Page